Before the pandemic, top contractor received billions from government to help prepare the nation for biowarfare

The Trump administration this month announced that one of its largest pandemic-related contracts would go to a little-known biodefense company named Emergent BioSolutions. The $628 million deal to help manufacture an eventual vaccine cemented Emergent’s status as the highest-paid and most important contractor to the HHS office responsible for preparing for public health threats and maintaining the government’s stockpile of emergency medical supplies. Emergent has long been the government’s sole provider of BioThrax, a vaccine for anthrax poisoning. Emergent’s advocacy for biodefense spending over more than a decade was aided by influential allies in Washington and tens of millions of dollars in lobbying campaigns. “It has strategically placed itself to be, let’s just say, the company that can’t fail,” said a former senior government official who worked with Emergent on stockpile operations. The company that would become Emergent began as BioPort Corp., formed in 1998 to buy an aging, state-owned company in Lansing, Mich., that was the only licensed supplier of anthrax vaccine to the Pentagon. The Pentagon … awarded a $29 million no-bid contract for the anthrax vaccine, BioThrax. Controversy swamped the operation. Hundreds of U.S. troops who received the BioThrax treatment complained of bad reactions, such as headaches and nerve problems. Some troops risked courts-martial by refusing vaccination. Emergent spent nearly $4 million on lobbying last year alone.

Note: To understand the huge influence of lobbying and profits on the development and stockpiling of vaccines, don’t miss reading this entire, eye-opening article. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and vaccines from reliable major media sources.

Go to Source
Author: {Want To Know}

Comments